Healthcare services company Astrana Health missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 48.5% year on year to $972.5 million. Next quarter’s revenue guidance of $1.02 billion underwhelmed, coming in 1.1% below analysts’ estimates. Its non-GAAP profit of $0.80 per share was 9.6% above analysts’ consensus estimates.

Is now the time to buy ASTH? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Astrana Health’s second quarter was met with a positive market response, as management highlighted several drivers behind the results. The company saw continued demand from payer and provider partners, maturation of value-based care cohorts, and disciplined medical cost trend management. CEO Brandon Sim attributed operating leverage improvements to the company’s proprietary AI-native healthcare operating system, which has enabled more efficient workflows and reduced general and administrative expenses. The integration of the Prospect Health acquisition also contributed to overall performance, with gross provider retention above 99% and expected operating expense synergies at the high end of targeted ranges.

Looking forward, Astrana Health’s guidance is rooted in investments aimed at accelerating growth across new and existing markets, particularly through Medicare Advantage and full risk arrangements. Management emphasized that a substantial portion of outperformance will be reinvested into provider and payer growth opportunities, including new contracts and tuck-in acquisitions. CFO Chan Basho noted, “These investments will generate attractive long-term returns while further strengthening our earnings power over time,” with ongoing improvements in operating leverage and continued maturation of risk cohorts positioned as key contributors to future profitability.

Key Insights from Management’s Remarks

Management identified expanding value-based care, leveraging AI-driven operating improvements, and strategic market expansion as core drivers of Q2 performance, while also addressing the impact of one-time events and ongoing cost management.

• AI-powered operating leverage: Astrana Health’s proprietary AI platform reduced claims and referral management handling times by over 50%, creating operational capacity equivalent to 60 full-time employees and lowering general and administrative expenses as a percentage of revenue.
• Full risk contract maturation: The company reported that approximately 81% of capitation revenue and 42% of membership now comes from full risk arrangements, with new cohorts reaching profitability more quickly due to improved risk prediction and operational execution.
• Prospect Health integration: Management highlighted successful integration of Prospect onto the Astrana platform, resulting in gross provider retention above 99% and operating expense synergies tracking at the high end of the $12 million–$15 million target range.
• Medical cost trend discipline: Year-to-date medical cost trends were slightly better than the 5.2% assumption, driven by stable inpatient admissions in Medicare and effective use of AI-enabled care navigation for lower-risk patients, while commercial segment costs ran slightly above expectations but remained manageable.
• Strategic portfolio rebalancing: The company is transitioning Medi-Cal members in California from professional to full risk arrangements, aiming to better align performance with financial outcomes, while expanding Medicare Advantage agreements in several states to offset ongoing Medicaid attrition.

Drivers of Future Performance

Astrana Health’s outlook is driven by targeted investments in growth opportunities, ongoing operating leverage from its AI platform, and disciplined management of risk and cost trends.

• Growth through Medicare Advantage: Management expects a higher proportion of revenue to come from Medicare programs as Medicaid attrition continues, with new Medicare Advantage agreements in Hawaii, Texas, and California set to drive membership and revenue growth into next year.
• Reinvestment for long-term returns: The company is reinvesting mid- to high-single-digit millions from current outperformance into onboarding new payer and provider contracts, strategic acquisitions, and early-stage risk cohorts, which are expected to contribute to earnings over the medium term.
• Ongoing cost management and automation: Continued reductions in general and administrative costs and further automation of member and administrative interactions are expected to sustain operating margin improvements and mitigate potential cost pressures, especially as full risk arrangements scale.

Catalysts in Upcoming Quarters

Looking ahead, our analyst team will be closely monitoring (1) the pace and profitability of transitioning more Medicaid and exchange members to full risk arrangements, (2) incremental contributions from new Medicare Advantage contracts in expansion markets like Texas and Hawaii, and (3) continued realization of operating expense synergies from the Prospect Health integration. Progress in scaling AI-enabled automation across administrative and clinical workflows will also be a key indicator of execution.

Astrana Health currently trades at $35.75, up from $34.13 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.